Review on Targeting the DNA Damaging Pathway: PARPi and Beyond1
Multidisciplinary Sarcoma Tumor Board2
Original Article
Case Report
Erratum
Disclosure:
1. The series “Targeting the DNA Damaging Pathway: PARPi and Beyond” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Shaheenah Dawood served as the unpaid Guest Editor for the series.
2. The series “Multidisciplinary Sarcoma Tumor Board” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. William Tseng is serving as the unpaid Guest Editor for the series.
